Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw

Frontiers in Bioscience - Elite

Volumn 3 E, Issue 1, 2011, Pages 364-370

  Marini, Francesca ^a   Tonelli, Paolo ^a   Cavalli, Loredana ^a   Cavalli, Tiziana ^a   Masi, Laura ^a   Falchetti, Alberto ^a   Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Bisphosphonates; Gene polymorphisms; Metastases; Mevalonate pathway; Osteonecrosis; Pharmacogenetics; Review

Indexed keywords

FRUCTOSE BISPHOSPHATE; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; GERANYLTRANSFERASE; IMIDAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; DRUG INDUCED DISEASE; EXPLORATORY RESEARCH; FEMALE; GENE FREQUENCY; GENE TARGETING; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE MYELOMA; PHARMACOGENETICS; PROSTATE CANCER; RETROSPECTIVE STUDY; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; GENETIC PREDISPOSITION; GENETICS; ITALY; JAW DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GERANYLTRANSTRANSFERASE; HUMANS; IMIDAZOLES; ITALY; JAW DISEASES; MALE; MULTIPLE MYELOMA; OSTEONECROSIS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 79957812216     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. R. Rizzoli, N. Burlet, D. Cahall, P. D. Delmas, E. F. Eriksen, D. Felsenberg, J. Grbic, M. Jontell, R. Landesberg, A. Laslop, M. Wollenhaupt, S. Papapoulos, O. Sezer, M. Sprafka, J. Y. Reginster: Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42, 841-847 (2008)
2. S. Khosla, D. Burr, J. Cauley, D. W. Dempster, P. R. Ebeling, D. Felsenberg, R. F. Gagel, V. Gilsanz, T. Guise, S. Koka, L. K. McCauley, J. McGowan, M. D. McKee, S. Mohla, D. G. Pendrys, L. G. Raisz, S. L. Ruggiero, D. M. Shafer, L. Shum, S. L. Silverman, C. H. Van Poznak, N. Watts, S. B. Woo, E. Shane: American Society for Bone and Mineral Research: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22, 1479-1491 (2007) (Pubitemid 351229318)
3. J. P. Bilezikian: Osteonecrosis of the jaw - Do bisphosphonates pose a risk? N Engl J Med 355, 2278-2281 (2006) (Pubitemid 44837776)
4. R. E. Coleman: Optimizing treatment of bone metastases by Aredia (TM) and Zometa (TM) Breast Cancer 7, 361-369 (2000)
5. A. Badros, D. Weikel, A. Salama, O. Goloubeva, A. Schneider, A. Rapoport, R. Fenton, N. Gahres, E. Sausville, R. Ord, T. Meiller: Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24, 945-952 (2006) (Pubitemid 46638849)
6. American Dental Association Council on Scientific Affairs: Dental Management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 137, 1144-1150 (2006)
7. American Association of Oral and Maxillofacial Surgeons. Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons eds. Rosemont, IL, USA (2006)
8. R. E. Marx: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61, 1115-1117 (2003) (Pubitemid 37064711)
9. S. L. Ruggiero, B. Mehrota, T. J. Rosenberg, S. L. Engroff: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62, 527-534 (2004) (Pubitemid 38542516)
10. I. R. Reid, M. J. Bolland, A. B. Grey: Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41, 318-320 (2007) (Pubitemid 47199147)
11. M. Ardine, D. Generali, M. Donadio, S. Bonardi, M. Scoletta, A. M. Vandone, M. Mozzati, O. Bertetto, A. Bottini, L. Dogliotti, A. Berruti: Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol 2006, 17, 1336-1337 (2006) (Pubitemid 44288231)
12. S. R. Cummings, A. V. Schwartz, D. M. Black: Alendronate and atrial fibrillation. N Engl J Med 356, 1895-1896 (2007)
13. F. Marini, A. Falchetti, S. Silvestri, Y. Bagger, E. Luzi, A. Tanini, C. Christiansen, M. L. Brandi: Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term aminobisphosphonate treatment in postmenopausal osteoporosis. Curr Med Res Opin 24, 2609-2615 (2008)
14. S. Carbonell Sala, A. Falchetti, V. Martineti, F. Marini, F. Del Monte, L. Masi, N. Fossi, A. Amedei, F. Franceschelli, A. Tanini, M. L. Brandi: Intron 1 polymorphism (A/C) of FDPS gene: A new genetic marker for N-BPs therapy response? Proceeding of The ASBMR XXVII Annual Meeting, Nashville, USA, 2005, Abstract SA121. J Bone Miner Res 20(suppl 1), s1-s512 (2005)
15. M. E. Sarasquete, R. García-Sanz, L. Marín, M. Alcoceba, M. C. Chillón, A. Balanzategui, C. Santamaria, L. Rosiñol, J. De La Rubia, M. T. Hernandez, I. Garcia-Navarro, J. J. Lahuerta, M. González, J. F. San Miguel: Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112, 2709-2712 (2008)
16. N. M. Jackson, T. A. Kocarek: Suppression of CYP2B induction by alendronate-mediated farnesyl diphosphate synthase inhibition in primary cultured rat hepatocytes. Drug Metab Dispos 36, 2030-2036 (2008)
17. L. H. Saltman, A. Javed, J. Ribadeneyra, S. Hussain, D. W. Young, P. Osdoby, A. Amcheslavsky, A. J. Van Wijnen, J. L. Stein, G. S. Stein, J. B. Lian, Z. Bar-Shavit: Organization of transcriptional regulatory machinery in osteoclast nuclei: compartimentalization of Runx1. J Cell Physiol 204, 471-480 (2005)
18. F. Goodsaid, F. Fruhe. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 7, 773-782 (2006) (Pubitemid 44225912)
19. H. Haga, R. Yamada, Y. Ohnishi, Y. Nakamura, T. Tanaka: Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190, 562 genetic variations in the human genome. Single-nucleotide polymorphism. J Hum Genet 47, 605-610 (2002) (Pubitemid 36083261)